secwatch.observer — SEC 8-K summary
======================================

Issuer:     Quince Therapeutics, Inc. (QNCX)
CIK:        0001662774
Form:       8-K
Filed at:   2026-08-27T20:30:17+00:00
Accession:  0001193125-26-371389
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Quince Therapeutics President Charles Ryan to depart Sept 8, 2026
-----------------------------------------------------------------

- President Charles Ryan's last day of employment is September 8, 2026; departure announced August 23, 2026.
- Ryan eligible for severance under Executive Change in Control and Severance Agreement dated September 1, 2023.
- Severance terms described in definitive proxy statement filed August 25, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1662774/000119312526371389/0001193125-26-371389-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1662774/000119312526371389/d124795d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-371389

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer